Advanced Life Sciences Appoints Director of Biological Sciences
David A. Eiznhamer, Ph.D., to help expand laboratory capabilities

Woodridge, IL, June 10, 2003 - Advanced Life Sciences (ALS) has appointed David A. Eiznhamer, Ph.D. as Director of Biological Sciences, announced ALS Chief Executive Officer Michael T. Flavin, Ph.D.

Highly regarded as an experienced scientific leader with expert knowledge in the field of pre-clinical drug development, Dr. Eiznhamer will oversee all biological operations including high throughput screening, mechanism of action investigations and biopharmaceutical profiling at ALS.

"Dave's addition to our already stellar scientific team will help Advanced Life Sciences' expansion of laboratory capabilities to now include biological science's in addition to our already existing chemistry and pharmaceutical sciences operations," said Dr. Flavin. "We are delighted that he has decided to come on board."

Advanced Life Sciences recently purchased a new facility in Woodridge that will house the company's corporate headquarters and R&D laboratory facilities. Expansion of laboratory operations is intended to give Advanced Life Sciences more control over critical issues encountered in the early stages of drug discovery and development. The added laboratory capabilities will also enhance ALS' position as an attractive collaborative partner to other pharmaceutical and biotechnology companies. The new facility is anticipated to be completed in time for October occupancy.

Before joining Advanced Life Sciences, Dr. Eiznhamer was responsible for the setup and operation of pharmacology and biopharmaceutical profiling at deCODE genetics, Inc in Woodridge, IL. He previously served as clinical research coordinator at Loyola University Medical Center. Dr.Eiznhamer earned his doctorate in molecular biology at Loyola University of Chicago.

Advanced Life Sciences is a privately held biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation using its platform in natural products and chemical proteomics coupled with expertise in drug development. (